Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ on gauging macular degeneration

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research & Quality posts final 1technology assessment on the scientific validity of patient-reported outcomes for age-related macular degeneration, identifying vision-specific questionnaires such as NEI-VFQ and VF-14 as the most appropriate quality-of-life instruments that still correspond "moderately" with traditional visual performance measures. CMS' Medicare Coverage Advisory Committee has considered such issues when weighing available evidence supporting AMD treatments (2"The Gray Sheet" Nov. 28, 2005, p. 7)...
Advertisement

Related Content

MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
MCAC To Weigh Emerging Treatments For Age-Related Macular Degeneration
Advertisement
UsernamePublicRestriction

Register

MT023509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel